IMNM - NASDAQ
Immunome, Inc.
$19.81
-4.7%Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
At a Glance
Live SnapshotImmunome, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Immunome, Inc. Balance Sheet
IMNM • NASDAQ
| Immunome, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
653.5M | 143.4M | 98.7M | 20.3M | 49.2M | 39.8M | 2.5M | 1.6M | |
0.0 | 74M | 39.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
653.5M | 217.3M | 138.1M | 20.3M | 49.2M | 39.8M | 2.5M | 1.6M | |
0.0 | 0.0 | 289K | 847K | 4.3M | 850K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 847K | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 289K | 0.0 | 4.3M | 850K | 0.0 | 0.0 | |
0.0 | 0.0 | 1.3M | 1.5M | 3.1M | 2.3M | 579K | 509K | |
7.3M | 4M | 5M | 0.0 | 0.0 | 0.0 | 0.0 | 509K | |
660.8M | 221.3M | 144.7M | 22.6M | 56.6M | 42.9M | 3.1M | 2.1M | |
NON-CURRENT ASSETS | ||||||||
17.6M | 14.4M | 3.6M | 965K | 855K | 1.5M | 1.7M | 2.1M | |
210K | 0.0 | 100K | 0.0 | 100K | 100K | 0.0 | 100K | |
4.6M | 4.5M | 100K | 432K | 332K | 0.0 | 238K | 155K | |
22.4M | 18.9M | 3.8M | 1.4M | 1.3M | 1.6M | 1.9M | 2.3M | |
683.2M | 240.2M | 148.5M | 24M | 57.9M | 44.5M | 5.1M | 4.4M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
3.3M | 14.2M | 3.3M | 2.4M | 3.1M | 1.2M | 548K | 473K | |
3.3M | 14.2M | 3.3M | 2.4M | 3.1M | 1.2M | 548K | 473K | |
0.0 | 25.1M | 2.7M | 2.7M | 4.3M | 845K | 240K | 393K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 479K | 212K | 225K | |
0.0 | 63K | 310K | 229K | 317K | 0.0 | 239K | 387K | |
0.0 | 6.9M | 10.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
41.7M | 8M | 5M | 2M | 2M | 527K | 426K | 83K | |
45M | 54.3M | 21.8M | 7.3M | 9.7M | 3M | 1.7M | 1.6M | |
NON-CURRENT LIABILITIES | ||||||||
3.9M | 0.0 | 0.0 | 0.0 | 0.0 | 134K | 113K | 325K | |
0.0 | 0.0 | 5.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | -5.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 5.5M | 0.0 | 12K | 8K | 38.9M | 27.5M | |
3.9M | 4.8M | 6.8M | 62K | 12K | 142K | 39M | 28.1M | |
0.0 | 4.8M | 1.7M | 291K | 317K | 0.0 | 239K | 626K | |
48.8M | 59.1M | 28.7M | 7.4M | 9.7M | 3.2M | 40.7M | 29.7M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 57.9M | 44.5M | 0.0 | 27.5M | |
11K | 6K | 4K | 1K | 1K | 1K | 0.0 | 1K | |
1.4B | 696.9M | 342.7M | 132.7M | 127.3M | 95.7M | 927K | 907K | |
-728.2M | -515.8M | -222.8M | -116M | -79.1M | -54.4M | -36.6M | -26.1M | |
0.0 | 57K | 22K | 0.0 | -57.9M | -44.5M | 0.0 | -904K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 904K | |
634.3M | 181.2M | 119.9M | 16.7M | 48.2M | 41.3M | -35.6M | -25.2M | |
634.3M | 181.2M | 119.9M | 16.7M | 48.2M | 41.3M | -35.6M | -25.2M | |
SUMMARY | ||||||||
683.2M | 240.2M | 148.5M | 24M | 57.9M | 44.5M | 5.1M | 4.4M | |
210K | 74M | 39.6M | 0.0 | 100K | 100K | 0.0 | 100K | |
3.9M | 4.8M | 1.7M | 291K | 317K | 613K | 564K | 1.2M | |
-649.6M | -138.5M | -97M | -20M | -48.9M | -39.2M | -2M | -426K | |
87,045,008 | 87,045,008 | 87,045,008 | 87,045,008 | 87,045,008 | 87,045,008 | 87,045,008 | 87,045,008 |
SEC Filings
IMNM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 17, 2025 | December 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 15, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 06, 2025 | August 06, 2025 | 2025 |
Related Guides
Continue your IMNM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.